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Background:Cholesterol-loadedmacrophages are key mediators of atherosclerosis and demonstrate increased SMPDL3A
expression and secretion.
Results: SMPDL3A expression is stimulated by cholesterol, liver X receptor ligands, and cAMP and hydrolyzes nucleotide
phosphates.
Conclusion: SMPDL3A is a nucleotide phosphodiesterase secreted from cholesterol-loaded macrophages.
Significance: SMPDL3A possesses a novel enzymatic activity with potential relevance to atherosclerosis.
Cholesterol-loaded foam cell macrophages are prominent in
atherosclerotic lesions and play complex roles in both inflam-
matory signaling and lipid metabolism, which are underpinned
by large scale reprogramming of gene expression. We per-
formed amicroarray study of primary humanmacrophages that
showed that transcription of the sphingomyelin phosphodies-
terase acid-like 3A (SMPDL3A) gene is up-regulated after cho-
lesterol loading. SMPDL3A protein expression in and secretion
from primary macrophages are stimulated by cholesterol load-
ing, liver X receptor ligands, and cyclic AMP, and N-glycosy-
lated SMPDL3A protein is detectable in circulating blood. We
demonstrate for the first time that SMPDL3A is a functional phos-
phodiesterase with an acidic pH optimum. We provide evidence
that SMPDL3A is not an acid sphingomyelinase but unexpectedly
is active against nucleotide diphosphate and triphosphate sub-
strates at acidic and neutral pH. SMPDL3A is a major source of
nucleotidephosphodiesterase activity secretedby liverX receptor-
stimulated humanmacrophages. Extracellular nucleotides such as
ATP may activate pro-inflammatory responses in immune cells.
Increased expression and secretion of SMPDL3A by cholesterol-
loaded macrophage foam cells in lesions may decrease local con-
centrations of pro-inflammatory nucleotides and potentially rep-
resent a novel anti-inflammatory axis linking lipid metabolism
with purinergic signaling in atherosclerosis.
The intracellular accumulation of lipoprotein-derived lipids,
particularly cholesterol, transforms macrophages into foam cells,
andthearterial retentionof thesecells is ahallmarkofearlyathero-
genesis. Foamcells develop aphenotypedistinct fromtheirmono-
cyte precursors, which includes secretion of an array of pro-in-
flammatory cytokines (attracting further immune cells to the
lesion) and deposition of extracellularmatrix proteins, promoting
additional retention of lipoproteins (1). The cellular responses of
the macrophage to cholesterol loading represent a complex over-
lappingpatternof lipidmetabolism, storage and transport, inflam-
matory signaling and responses, extracellular matrix interactions,
andapoptoticpathways (2). Inhibitionandreversal ofmacrophage
foam cell formation are considered key candidates for therapeutic
targeting, and thus identifying the complex perturbations in gene
expression that underpin the transformation of macrophage to
foam cell is essential.
To further understand the changes in gene expression occur-
ring after foamcell formation,we conducted an oligonucleotide
microarray study using cholesterol-loaded primary human
monocyte-derived macrophages (HMDMs)2 as a foam cell
model. We observed that expression of the gene SMPDL3A
(sphingomyelin phosphodiesterase, acid-like 3A) is strongly
up-regulated by cholesterol loading. SMPDL3A is named for its
sequence homology to the well characterized acid sphingomy-
elinase (aSMase, encoded by the SMPD1 gene), with which it
shares 31% amino acid identity. Acid SMase hydrolyzes sphin-
gomyelin to produce phosphorylcholine and ceramide, a key
signalingmolecule in several apoptotic and stress-related path-
ways (3). aSMase is capable of hydrolyzing sphingomyelin in
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oxidized LDL particles, transforming them into a more aggre-
gation-prone form that is more readily retained by arterial pro-
teoglycans (4, 5). The activity of aSMase appears pro-athero-
genic in vivo, where it promotes the retention of lipoprotein in
the subendothelium and contributes to the growth of athero-
sclerotic plaques in the aortae of mice (6).
SMPDL3Awas originally identified as a gene up-regulated in
bladder tumor versus healthy urothelium tissue (7), and more
recently it has been shown to be regulated by liver X receptor
(LXR) ligands in human macrophage cell lines (8, 9). Beyond
these observations, little is known about the biochemistry or
function of SMPDL3A. Based on the strong up-regulation of
SMPDL3A expression in cholesterol-loaded macrophages and
the established involvement of its homolog aSMase in the pro-
gression of atherosclerosis, we explored the biology of this
poorly characterized gene further. In this study, we report that
cellular expression and secretion of SMPDL3A are not only
increased by cholesterol and synthetic LXR ligands in primary
human macrophages but also by cyclic AMP. We present the
first experimental evidence that SMPDL3A is a functional met-
allophosphoesterase and, despite having no detectable activity
toward sphingomyelin, possesses a nucleotide phosphodiester-
ase activity, particularly strongly against nucleotide triphos-
phates. Indeed,we show that SMPDL3A is themajor nucleotide
phosphodiesterase secreted by human THP-1 macrophages
after LXR stimulation. This unexpected activity, together with
its up-regulation in cholesterol-loaded macrophages, indicates
the regulation and enzymology of SMPDL3A are distinct from
aSMase and may play a novel role in the pathobiology of
atherosclerosis.
EXPERIMENTAL PROCEDURES
Materials—All p-nitrophenol-conjugated substrates, nucle-
otide phosphates (ATP, ADP, AMP, cAMP, GTP, GDP, cGMP,
UTP, UDP, and CTP), -methyl cyclodextrin, cholesterol,
22-hydroxycholesterol, T-0901317, phorbol 12-myristate
13-acetate (PMA), dibutyryl-cAMP (Bt2cAMP) and forskolin
were obtained from Sigma. White cell buffy coat concentrates
and human serum were supplied by the New South Wales Red
Cross Blood Transfusion Service, Sydney, Australia. LDL,
acetylated LDL (AcLDL), and lipoprotein-deficient serum
(LPDS) were prepared as described (10). Soluble cholesterol/-
methyl cyclodextrin (cholesterol-CD) complexes were pre-
pared as described previously (11). Rabbit polyclonal anti-hu-
man SMPDL3A (ab68533) and anti-human CD39 (ab108248)
antibodies was obtained from Abcam. Rabbit polyclonal anti-
mouse SMPDL3A (ARP52244) and anti-human SMPDL3B
(ARP33875) antibodies were purchased from Aviva Systems
Biology. AlexaFluor 488- and 555-conjugated F(ab)2 anti-
bodies were obtained from Cell Signaling Technologies. [3H]-
Choline methyl-labeled sphingomyelin was obtained from
PerkinElmer Life Sciences. Unlabeled bovine brain sphingomy-
elin was purchased from Avanti Polar Lipids.
Cell Culture—Human monocytes were isolated from white
cell concentrates of healthy donors as described previously (12).
After differentiation for 3 days in the presence of 25 ng/ml
M-CSF, the cells were washed and enriched with cholesterol by
incubation in RPMI 1640 medium including 10% (v/v) lipopro-
tein-deficient serum (LPDS) and either acetylated LDL (50 g
protein/ml) for 2 days or cholesterol-CD (20g cholesterol/ml)
for 24 h. In some experiments, cells were treated with
T-0901317 (1 M) or 22-hydroxycholesterol (10 M) for 24 h.
CHO-Trex cells (Invitrogen) were cultured in Ham’s F-12
complete medium with 10% (v/v) fetal bovine serum and HEK-
Trex cells (Invitrogen) in DMEM complete medium with 10%
(v/v) fetal bovine serum.
THP-1 cells were maintained in RPMI 1640 medium supple-
mentedwith10%(v/v) fetal bovine serum.THP-1monocyteswere
differentiated intomacrophagesby additionofPMAat a final con-
centration of 50 ng/ml for 72 h prior to experimental setup.
Microarray Analysis—Total RNA was isolated using RNeasy
reagent (Qiagen), amplified using the MessageAmp aRNA kit
(Ambion), and indirectly labeled using Alexa 555 dye (Invitro-
gen). Reference aRNA was pooled from the test aRNA samples
and labeled with the Alexa 647 dye (Invitrogen). 5 g of Alexa
555-labeled aRNA was mixed with 5 g of Alexa 647-labeled
aRNA. The aRNA mix was hybridized using a 50% formamide
slide stack against Compugen human oligonucleotide microar-
rays (Institute for Molecular Bioscience, University of Queen-
sland). Samples included HMDM from two separate donors,
and hybridizations were performed in technical replicates.
Hybridization signalswere collected using aG2565BAmicroar-
ray scanner (Agilent). Intensity and background data for each
spot were calculated using Imagene (BioDiscovery Inc., El
Segundo, CA). Microarray data were analyzed using the Gene-
Spring software (Agilent).
Quantitative Real Time PCR Measurements—Reverse tran-
scription was performed according to the manufacturer’s pro-
tocol for SuperScript III First Strand cDNA synthesis kit (Invit-
rogen). Quantitative reverse transcriptase-PCR (QRT-PCR)
was performed using SensiMix SYBR (Bioline) on a Corbett
Rotorgene 3000 machine and analyzed using Rotor-Gene 6
Version 6.0 (Build 27). Primer pairs (supplemental Table 1)
used for the amplification reaction of various genes from
cDNAs were designed using NCBI PrimerBlast. Changes in
gene expression levels were determined by normalizing mRNA
levels of the gene of interest to the mRNA level of the house-
keeping gene (-actin or HPRT) and quantified using the Ct
method. Melting curve analysis was performed to confirm pro-
duction of a single product in each reaction.
Generation of a Monoclonal Antibody to Human SMPDL3A—
Mice were immunized with a purified synthetic peptide corre-
sponding to amino acids 316–327 of human SMPDL3A
(sequence FQYDPRDYKLLD), and a monoclonal hybridoma
cell line (6E3G4A1) producing IgG1 antibodies was established
from these animals (EZBioLab, IN).
HPLC Analysis of Cellular Cholesterol—Cells were lysed in
ice-cold 0.2 N sodium hydroxide, and free cholesterol and cho-
lesteryl ester were determined by reverse phase HPLC after
extraction into methanol/hexane as described previously (10).
Cholesterol concentration was expressed relative to cellular
protein, as determined by BCA assay (Pierce).
Western Blotting—Protein samples were prepared by boiling
in SDS-PAGE sample buffer containing 1% SDS, 100 mM DTT,
and 60mMTrisHCl, pH 6.8. Samples were separated on 4–12%
gradient bis-Tris gels (Invitrogen) and electroblotted onto
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nitrocellulosemembranes using iBlot transfer apparatus (Invit-
rogen). Membranes were blocked by incubation in phosphate-
buffered saline (PBS) containing 4% (w/v) skim milk and 0.1%
(v/v) Tween 20 for 1 h at room temperature. SMPDL3AWest-
ern blots were probedwith either undiluted 6E3G4A1hybridoma
supernatant or commercial primary antibody diluted 1:1000 in
blocking buffer overnight, followed by either anti-mouse or anti-
rabbit IgG-horseradish peroxidase-conjugated secondary anti-
body for 1 h (Jackson ImmunoResearch). Blots were visualized
using enhanced chemiluminescence reagents (GE Healthcare)
and either LAS-4000mini (Fuji) or Gel Doc XR (Bio-Rad) CCD
imaging systems.Quantitation of immunoreactive bandswas per-
formed using Image Lab Version 4.1 software (Bio-Rad). Tomea-
sure specifically the SMPDL3A protein levels in cell lysates, the
52-kDa reactive band was chosen for quantitation.
For Western blotting of secreted proteins in conditioned
media, cells were washed with PBS to remove traces of serum
proteins, incubated with fresh serum-free medium containing
experimental treatment for 24 h, before the medium was har-
vested and spun down to remove any cellular debris, and loaded
neat onto gels with SDS-PAGE sample buffer. Where required,
secreted proteins were either concentrated by acetone precipi-
tation (1 volume of conditioned media to 4 volumes of cold
acetone at20 °C for 1 h, centrifugation, air-drying, and resus-
pension in SDS-PAGE sample buffer) or by aMicrocon 10-kDa
centrifugal filter device (Millipore). Human and mouse plasma
samples were analyzed after dilution into SDS-PAGE sample
buffer and loading the equivalent of 200 nl of plasma per well.
Construction of SMPDL3A Expression Plasmid—A plasmid
bearing the full-length sequence-verified human SMPDL3A
open reading frame (IMAGE clone 100009862; Open Biosys-
tems) was used as a template for all cloning experiments. A tetra-
cycline-inducible C-terminal His6-tagged SMPDL3A expression
construct was produced by amplifying the SMPDL3AORF using
the HindIII-containing primers 5-GAGAAAGCTTACCATGG-
CGCTGGTGCG-3 and 5-TCTCAAGCTTCTAGTGATGGT-
GATGGTGATGGTAATTGTGCTTTAT-3. The resultingPCR
product was digested and ligated into the HindIII site of pcDNA
4/TO (Invitrogen) to create pcDNA 4/TO-SMPDL3A6His. The
correct sequence andorientationof this constructwere confirmed
by DNA sequencing.
Cellular Expression of SMPDL3A—The pcDNA 4/TO-
SMPDL3A-His6 construct was transfected into CHO-Trex
cells (Invitrogen) using FuGENE 6 reagent (Roche Applied Sci-
ence). Transfected cells were maintained under blasticidin and
Zeocin (Invitrogen) selection, and a stable clonal cell line was
established (CHO-SMPDL3A). Expression of SMPDL3A was
induced by addition of tetracycline (1 M) and overnight (16
h) incubation. A stable tetracycline-inducible HEK cell line was
created in a similar manner by transfecting the pcDNA 4/TO-
SMPDL3A-His6 plasmid into HEK-Trex cells (Invitrogen).
Purification of Secreted Recombinant SMPDL3A from CHO-
SMPDL3A Cells—CHO-SMPDL3A cells were plated onto
25-cm2 cell culture dishes and grown to confluency in F-12
media with 10% FCS. Cells were washed three times with PBS,
and themedia were replacedwith serum-free F-12 containing 1
M tetracycline to induce SMPDL3A expression. After 24 h, the
conditioned media were harvested, filtered through a 0.22-m
filter, and adjusted to pH8.0 (with 20mMTris) and 500mM final
NaCl concentration.Media were loaded onto aHisTrap nickel-
agarose column (GE Healthcare) connected to an NGC chro-
matography system (Bio-Rad). The columnwaswashedwith 10
column volumes of wash buffer (20 mM Tris, pH 8.0, 500 mM
NaCl), followed by a gradient of 0–500 mM imidazole over 20
column volumes. Eluted fractions were analyzed by Western
blotting (6E3G4A1 anti-SMPDL3A monoclonal) and enzyme
assay, using ATP and p-nitrophenol thymidine monophos-
phate substrates.
Knockdown of SMPDL3A Expression—Anti-human SMPDL3A
(catalog number 1225141) and universal negative control
scrambled siRNA (Stealth siRNA) were purchased from Invit-
rogen. 50 pmol of anti-SMPDL3A or scrambled siRNAnegative
control were transfected into 1  106 PMA-differentiated
THP-1 human macrophages using Lipofectamine RNAiMAX
liposomes (Invitrogen) according to themanufacturer’s recom-
mendations. Cells were incubated with siRNA for 24 h, before
replacement with serum-free RPMI 1640 media containing
experimental treatments. Efficiency of SMPDL3A siRNA
knockdown was assessed using QRT-PCR and anti-SMPDL3A
Western blotting.
Removal of N-Linked Glycans—N-Linked glycans were enzy-
matically removed using PNGaseF (New England Biolabs)
according to the manufacturer’s instructions. For denaturing
conditions, glycoprotein samples were heated to 100 °C for 10
min and then incubated with PNGaseF (500 units) for 1 h at
37 °C. For native conditions, glycoprotein samples were treated
directly with 500 units of PNGaseF for 16 h at 37 °C. In each
case, control samples were subjected to identical treatment but
without addition of PNGaseF enzymes. Relative molecular
masses of control and PNGaseF-digested glycoprotein samples
were measured by SDS-PAGE and Western blotting.
Confocal Microscopy—Cells were fixed using cold 4% (v/v)
paraformaldehyde in PBS for 15 min, followed by a 30-min
incubation in permeabilization buffer (0.5% (w/v) saponin in
PBS) supplemented with 10% (v/v) whole serum of the same
species as the secondary antibody. Cells were probed for 1 h at
room temperature with primary antibody, washed, and then
incubated with F(ab)2 fragment antibodies (Cell Signaling
Technology) conjugated to either AlexaFluor 488 or Alex-
aFluor 555 for 1 h at room temperature. Finally, cells were
washed, mounted with Mowiol 4–88, and imaged using an
Olympus FV1000 confocal laser scanning microscope and a
60 oil immersion lens. False coloring,merging, and analysis of
images were performed using ImageJ 1.46 software (National
Institutes of Health).
Phosphodiesterase Activity Assays—Phosphodiesterase activ-
ities were determined using a panel of p-nitrophenol-conju-
gated synthetic substrates. Substrate cleavage was monitored
by measuring the increase in absorbance at 405 nm. Absor-
bances were converted to molar values using an extinction
coefficient for p-nitrophenol of 18,000 M1 cm1. Substrates
tested were as follows: p-nitrophenol phosphate (p-NPP),
bis-(p-nitrophenyl) phosphate (bis-p-NPP), p-nitrophenyl-
phosphorylcholine (p-NPPC), and p-nitrophenyl thymidine
5-monophosphate (p-NP-TMP). Activity was assayed with
125 mM TrisHCl (for pH 7.0 and above) or 125 mM sodium
SMPDL3A, Cholesterol-regulated Nucleotide Phosphodiesterase
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acetate (below pH 7.0) final concentration buffers and 20 mM
p-nitrophenyl-conjugated substrate. Where indicated, reac-
tions were supplemented with metal ion (5 mM). All reactions
occurred at 37 °C.
Sphingomyelinase Assays—Sphingomyelinase activity was
determined in cell lysates and conditioned media using 3H-ra-
diolabeled sphingomyelin as described previously (13). Briefly,
choline [3H]methyl-labeled sphingomyelin (final concentra-
tion, 0.1 Ci/ml) and unlabeled bovine brain sphingomyelin
(final concentration 500M) in ethanol were dried under nitro-
gen and reconstituted in 0.6% Triton X-100 and reaction buffer
(100mM sodium acetate, 5mMZn2, pH 5.5, for acidic reaction
conditions, or 100 mM Tris, 5 mM Mg2, pH 7.5, for neutral
conditions) with sonication. For assays of cell lysates, 10 l of
cell lysates, adjusted to each contain 50g of total protein, were
mixed with 90 l of sphingomyelin reaction buffer. For assays
of conditioned media, 50 l of media were mixed with 50 l of
sphingomyelin reaction buffer. Reactions were allowed to pro-
ceed for 2 h at 37 °C before quenching and extraction of liber-
ated [3H]choline by addition of 375 l of a 1:2 v/v chloroform/
methanol mixture. Samples were vortexed, and an additional
125 l of chloroform was added, vortexed again, and 125 l of
water was added. Samples were centrifuged at 14,000 rpm for 1
min, and the upper aqueous layer was collected and analyzed by
3H scintillation counting.
For serum supplementation studies, pooled human serum
from healthy donors was first heat-inactivated (HI) by incuba-
tion at 56 °C for 30 min. Choline [3H]methyl-labeled sphingo-
myelin (0.5 Ci/ml final concentration) was equilibrated into
serum lipoproteins by mixing with HI serum at room temper-
ature for 1 h. 50 l of equilibrated HI serum/[3H]sphingomy-
elin was mixed with 50 l of tetracycline-induced CHO
SMPDL3A conditioned media and incubated for 2 h at 37 °C
before extraction and scintillation counting of liberated [3H]-
choline as described above. A negative control supplemented
with water instead of conditioned media was included to dem-
onstrate heat inactivation of endogenous serum sphingomyeli-
nase activity.
Sphingomyelinase activity was additionally assayed in condi-
tioned media using an Amplex Red enzymatically coupled
fluorescence assay (Invitrogen). Background levels of choline,
which would result in spuriously high baseline readings, were
eliminated from samples by buffer exchange (10-kDa Centri-
con centrifugal concentrator;Millipore). To begin the reaction,
100 l of buffer-exchanged medium was mixed with 100 l of
sphingomyelinase assay buffer, which contained either 100 mM
Tris, pH 7.4, or 100mM sodium acetate, pH 5.5, and 5mMMg2
or 5 mM Zn2. Final reagent concentrations, common to all
conditions, were 50 M Amplex Red, 200 milliunits of horse-
radish peroxidase, 20 milliunits of choline oxidase, 800 milli-
units of alkaline phosphatase, 250 M sphingomyelin, and 0.1%
Triton X-100. Assays were incubated at 37 °C for the indicated
time. Amplex Red fluorescence was measured using a BMG
FLUOstar plate reader (excitation 544 nm/emission 590 nm).
Mass Spectrometric Measurement of Cellular Lipid Com-
position—HEK-SMPDL3A cells were grown to near confluence
in 75-cm2 flasks and treated with or without 1 M tetracycline
for 24 h (n  6 for each condition). Cells were harvested by
scraping into PBS, pelleted, resuspended in Tris-buffered
saline, pH 7.0, supplemented with 100 M butylated hydroxy-
toluene to prevent lipid oxidation, and lysed using an ultrasonic
probe. Protein concentrations of crude cell lysates were deter-
mined by BCA assay, and expression of SMPDL3A after tetra-
cycline induction was confirmed by Western blotting with
6E3G4A1 antibody. Total lipids were extracted using the
method of Bligh and Dyer (14). Extracted cellular lipids were
analyzed by liquid chromatography-tandem electrospray mass
spectrometry as described previously (15). Lipid concentra-
tions were normalized and expressed relative to extracted pro-
tein concentration.
Nucleotide Phosphodiesterase Activity Measurement—The
activity toward nucleotide phosphate substrates of concen-
trated cell-conditioned media from recombinant SMPDL3A-
expressing CHO cells was determined using aMalachite Green
inorganic phosphate release assay (Biomol Green, Enzo).
Excess free phosphate in the media, which could interfere with
the Malachite Green assay, was removed by buffer exchange
using a 10-kDa cutoff Centricon device (Millipore). Reaction
buffer included TrisHCl (125 mM, pH 7.5), Mg2 (5 mM), and
nucleotide phosphates (200 M) as indicated, at a final volume
of 100l. Reactions were incubated at 37 °C for 1 h, terminated
by adding 100l of Biomol Green reagent, and incubated for 15
min at room temperature before measuring absorbance at 620
nm. Absorbance values were converted to molarity by genera-
tion of a sodium phosphate standard curve.
HPLC Measurement of Adenosine Phosphates—Concentra-
tions of individual adenosine phosphate species arising from
the hydrolysis of ATP by SMPDL3A were determined by
reversed phase HPLC. Nucleotide phosphates were separated
on a 25-cm  4.6-mm C18 column (Phenomenex) using iso-
cratic elution with a 0.1 M KH2PO4, pH 6, mobile phase at 1
ml/min flow rate, with UV detection at 254 nm on a Perkin-
Elmer Life Sciences Series 200 HPLC system. Pure ATP, ADP,
and AMP standards were run at the start of each experiment to
determine elution times and response factors.
Human andMouse Ethics—Ethics approval for human blood
collection was obtained from the Sydney Local Health District
and the relevant collection site (Royal Prince Alfred Hospital),
and written informed consent was obtained from all donors.
C57/Bl6 mouse serum was collected with the approval of the
University of New South Wales Animal Care and Ethics
Committee.
RESULTS
SMPDL3A Expression and Secretion Is Up-regulated by
Cholesterol Loading and LXR Agonists in Primary Human
Macrophages—To identify genes differentially regulated in
human macrophages by cholesterol accumulation, oligonu-
cleotide microarray analysis was performed on HMDMs
obtained from two separate donors 	 cholesterol loading by
incubation with acetylated LDL (AcLDL) for 48 h (supplemen-
tal Table 2). SMPDL3A was among the most highly up-regu-
lated genes that passed all quality filters, with expression
increased by 4.35- and 3.35-fold in the two individual donors,
respectively. To validate the microarray data, HMDMs from
five different donors were incubated 	 AcLDL as above, and
SMPDL3A, Cholesterol-regulated Nucleotide Phosphodiesterase
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SMPDL3A mRNA expression was determined by quantitative
RT-PCR. Expression of SMPDL3A mRNA in cholesterol-
loaded cells was significantly increased in all five donors relative
to nonloaded controls (mean 3.97-fold increase; Fig. 1A).
To further demonstrate this increase in SMPDL3A mRNA
expression was due to cholesterol accumulation, HMDMs were
also separately loaded using soluble cholesterol--methyl cyclo-
dextrin complexes, which transfer cholesterol directly to cells
independently of receptor-mediated uptake. Effective cholesterol
loading of HMDMs under the above conditions was confirmed
using HPLC analysis of total cellular cholesterol (Fig. 1B). As for
AcLDL loading, SMPDL3A mRNA levels were significantly
increased inHMDMby cholesterol-CD loading (Fig. 1C), demon-
stratingSMPDL3AmRNAexpression is sensitive to increased cel-
lular cholesterol levels, regardless of the mechanism of sterol
uptake.
To measure levels of SMPDL3A protein, a custommonoclo-
nal antibody directed against a polypeptide sequence unique to
human SMPDL3A was created (6E3G4A1; supplemental Fig.
1). Using this antibody, expression of SMPDL3A protein in
HMDMcell lysateswasmeasured byWestern blotting. This iden-
tified two closely spaced bands of 52–54 kDa (Fig. 1D, inset),
FIGURE 1. SMPDL3A expression in cholesterol-loaded humanmonocyte-derivedmacrophages. A, SMPDL3AmRNA expression. HMDM from five individ-
ual healthy donors were incubated for 48 h in RPMI 1640 medium containing 10% (v/v) LPDS 	 AcLDL (50 g/ml), then mRNA expression measured by
QRT-PCR. SMPDL3A mRNA was normalized against the housekeeping gene (-actin) and expression in cholesterol-loaded HMDM expressed relative to
nonloaded cells. Data aremeans	 S.D. of four technical replicates. B, free cholesterol and cholesteryl estermassweremeasuredusing reverse phaseHPLC and
normalized for cell protein. Data are means	 S.D. for three determinations. C, SMPDL3AmRNA expression and comparison with SMPD1. HMDMwere treated
with AcLDL(50g/ml; 48 h), cholesterol/-methyl cyclodextrin (Chol-CD) (20g/ml; 24 h), or T-090317 (T-09, 1M; 24 h) and thenmRNA expressionmeasured
by QT-RT-PCR. SMPDL3AmRNA was normalized against the housekeeping gene (-actin), and expression was expressed relative to untreated cells. Data are
means	 S.D. of four determinations. D, SMPDL3A protein expression. HMDM cells treated as in C. Western blot analysis of SMPDL3A in cell lysates (15 g of
protein/lane)using6E3G4A1monoclonal antibody.Data aremeans	S.D. of threedeterminations.Panel inset showsa representativeblot.E,SMPDL3Aprotein
secretion. HMDM¼zaq;A cells washed with serum-free media and then treated as above but using serum-free media. Conditionedmedia were concentrated
and analyzed by anti-SMPDL3AWestern blot. *, p
 0.05; **, p
 0.01; ***, p
 0.001 (unpaired two-tailed t-tests).
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consistentwith thepredictedmolecularmass of SMPDL3A (51.26
kDa). Levels of intracellular SMPDL3A protein were significantly
higher incells loadedwithcholesterolusingAcLDLorcholesterol-
CD, reflecting the transcriptional response (Fig. 1D).
The up-regulation of SMPDL3AmRNA and protein expres-
sion in primary humanmacrophages by cholesterol loading led
us to examine the sequence of the putative SMPDL3Apromoter
region for sterol or lipid-related regulatory motifs. Bioinfor-
matic analysis of the genomic nucleic acid sequence upstream
of the SMPDL3A ORF using MatInspector software (16) iden-
tified a potential LXR element 160 bp upstream from the tran-
scription start site (sequenceAGGTCAGGCGAACTGA). LXR
elements were recognized by LXR-retinoid X receptor het-
erodimeric transcription complexes after activation by binding
to oxysterol ligands and are important for the regulation of
several key cholesterol-responsive genes, such as ABCA1 and
ABCG1 (17). Treatment of HMDMs with the synthetic LXR
ligand T-0901317 strongly stimulated SMPDL3A mRNA
(Fig. 1C) and protein (Fig. 1D) expression, confirming that
SMPDL3A expression is LXR-responsive. SMPDL3A mRNA
was also up-regulated by treatment with a second LXR ligand,
22-hydroxycholesterol (data not shown). These results are con-
sistent with other studies published while this work was under-
way, which demonstrated that SMPDL3AmRNA expression is
increased by LXR ligands in the immortalized human leukemic
THP-1 macrophage cell line and in undifferentiated human
peripheral blood mononuclear cells (8, 9).
To determinewhether SMPDL3Awas secreted fromHMDMs,
cells were incubated for 24 h in serum-free medium, and the
media were then harvested, concentrated by acetone precipita-
tion, and analyzed byWestern blotting. Two closely spaced bands
(52–55 kDa) of SMPDL3A were detected (Fig. 1E), similar to
those observed in HMDMcellular lysates (Fig. 1B). As for cellular
mRNAandprotein expression, secretionof SMPDL3Awas signif-
icantly increasedby cholesterol loadingwith eitherAcLDLor cho-
lesterol-CD and treatment with LXR agonist.
SMPDL3A Expression and Secretion Is Regulated by Intracel-
lular cAMP—MatInspector promoter region analysis also
revealed the presence of putative cyclic AMP-responsive ele-
ments, suggesting that SMPDL3A expression may also be reg-
ulated by cellular cAMP (potential cAMP-response element-
binding protein site at 281 bp upstream of transcription
start site TGACATCA). To investigate this, HMDMs were
treated for 24 h with Bt2cAMP (amembrane-permeable analog
of cAMP) and forskolin (an activator of adenylyl cyclase,
which increases cAMP production) before measurement of
SMPDL3A protein expression. Treatment with Bt2cAMP, for-
skolin, or forskolin combined with Bt2cAMP led to significant
up-regulation in the expression of SMPDL3AmRNA (Fig. 2A),
intracellular protein levels (Fig. 2B), and secretion (Fig. 3C),
FIGURE 2. SMPDL3AmRNA expression, protein expression, and secretion is regulated by cellular cAMP. A, SMPDL3AmRNA expression and comparison
with SMPD1. HMDM were incubated for 24 h in RPMI 1640 medium containing 10% FCS plus dibutyryl-cAMP (db-cAMP, 1 mM) and/or forskolin (100 M) as
indicated.mRNAwasmeasured byQRT-PCR and normalized to-actin as described above. Data aremeans	 S.D. of four determinations. B, SMPDL3Aprotein
expression. HMDMcells treated as inA. Western blot analysis of SMPDL3A in cell lysates (15gof protein/lane). Data aremeans	 S.D. of three determinations.
C, SMPDL3A protein secretion. HMDM cells washed with serum-free media and then treated as above but using serum-free media. Conditioned media were
concentrated and analyzedby anti-SMPDL3AWestern blot.D, effect of PKA inhibition on SMPDL3A secretion. THP-1macrophageswere pretreatedwith 10M
H89 for 1 h prior to stimulation with 1mM Bt2cAMP, 100M forskolin for 24 h. Conditionedmedia were concentrated and analyzed by anti-SMPDL3AWestern
blot. Data are means	 S.D. of three determinations. *, p
 0.05; **, p
 0.01; ***, p
 0.001 (unpaired two-tailed t tests).
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indicating expression of SMPDL3A is indeed sensitive to cAMP
levels and that the cyclic AMP-responsive elements in the pro-
moter region of SMPDL3A may play a functional role in pri-
mary human macrophages.
Many downstream effects of cAMP stimulation aremediated
via protein kinase A (PKA) signaling. To determine whether
PKA was involved in the cAMP-dependent stimulation of
SMPDL3A secretion, THP-1 macrophages were pretreated
FIGURE3.Aminoacid sequence comparisonof SMPDL3Awithacid sphingomyelinaseandSMPDL3B. The amino acid sequences of humanSMPDL3Aand
close human homologs, SMPDL3B and aSMase (encoded by the SMPD1 gene), were aligned using ClustalW2. Asterisks indicate exact sequence matches, and
colons indicate conservative substitutions. Knownor predicted signaling regions are shaded in light gray and saposin domains in dark gray. Phosphodiesterase
consensus motifs are indicated using open boxes. Conserved residues known or predicted to be involved in metal binding are indicated by M. Known or
predicted N-linked glycosylation sites are indicated by N. The predicted glycosylphosphatidylinositol anchor attachment site at Ala-431 in SMPDL3B is
indicated by a light gray shaded box. Uniprot sequence accession numbers are SMPDL3A:Q92484, SMPDL3B:Q92485, and aSMase:P17405.
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with H89, a potent PKA inhibitor, prior to stimulation with
Bt2cAMP  forskolin. However, H89 had no effect on the
secretion of SMPDL3A (Fig. 2D). H89 pretreatment was itself
effective, as it significantly reduced the secretion of apolipopro-
tein E, which is known to be PKA-dependent (data not shown)
(18). This result indicates the up-regulation of SMPDL3A
secretion by raised cAMP levels is mediated by a PKA-inde-
pendent pathway.
Comparative Sequence and ExpressionAnalysis of SMPDL3A
and Its Homologs—SMPDL3A is named for its amino acid
sequence similarity to acid sphingomyelinase (aSMase),
encoded by the SMPD1 gene in humans. Alignment of the
translated amino acid sequences of SMPDL3A and aSMase
using BLAST reveals 31% amino acid identity and 48% overall
amino acid similarity. The amino acid sequence of SMPDL3A is
also highly similar (41% amino acid identity and 60% similarity)
to that of human SMPDL3B (sphingomyelin phosphodiester-
ase-like 3B), another poorly characterized potential phospho-
diesterase family member. SMPDL3A contains a highly con-
served example of the classical phosphoesterase G(D/G)NH
signature motif (Fig. 3, open boxes) (19), with only a single amino
acid (serine 111) deviating from a perfect match to the consensus
sequence. ClustalW2 multiple alignment of the amino acid
sequences of SMPDL3A, SMPDL3B, and aSMase revealed the key
residues of the GD/GNH phosphoesterase motif in SMPDL3A to
be perfectly aligned with those of aSMase and SMPDL3B. All five
key metal-binding residues predicted from a homology model of
aSMase (20)were also found to be conserved andperfectly aligned
within thesequencesofSMPDL3A,SMPDL3BandaSMase (Fig.3,
indicated by boldfaceM).
Acid sphingomyelinases (including human aSMase) contain
the consensus motif NX3CX3N (where X is any amino acid;
indicated in boldface in Fig. 3), which is predicted to be
directly involved in the recognition of the phosphorylcholine
headgroup of their sphingomyelin substrates (20). In human
aSMase, the central cysteine (Cys-385) of the motif is also
involved in a disulfide bridge with Cys-431 (21). SMPDL3A and
SMPDL3Bboth deviate from this consensus sequence, contain-
ing a tyrosine substitution of the central cysteine residue, sug-
gesting this region may differ from aSMase both in terms of
three-dimensional structure and substrate recognition.
aSMase contains a sphingolipid activator protein (saposin)
domain in its N-terminal region (Fig. 3, dark gray shading) (22),
followed by a proline-rich linker. Saposins disrupt membrane
structure, facilitating access to individual phospholipid mole-
cules (23). In aSMase, this domain also plays a role in stabilizing
the structure of the enzyme (24). Notably, both SMPDL3A and
SMPDL3B lack any sequence homology to either the saposin
domain of aSMase or to the individual saposin A–D polypep-
tides. aSMase also contains anN-terminal 46-amino acid signal
peptide with a distinctive leucine-alanine repeat motif, which
directs the translated aSMase polypeptide into the endoplasmic
reticulum lumen and is required for its secretion (Fig. 3, light
gray shading) (25). Signal sequence analysis using the SignalP
4.1 algorithm (26) also predicts the presence of N-terminal sig-
naling peptides in both SMPDL3A and SMPDL3B, consistent
with the secretion of SMPDL3A into the media of human
macrophages (Figs. 1E and 2C). However, there is limited
homology between these two predicted signaling peptides or
with the signal region of aSMase, including a lack of the signa-
ture leucine-alanine repeat motif. The C-terminal domains of
SMPDL3A and SMPDL3B also display limited similarity to
each other. Analysis of this region with the PredGPI algorithm
(27) predicts a high confidence glycosylphosphatidylinositol
anchor attachment point at Ala-431 in the sequence of
SMPDL3B (Fig. 3, shaded box), which has recently been
experimentally confirmed (28). However, no such modifica-
tion is predicted or has yet been described experimentally for
SMPDL3A.
The aSMase is anN-glycoprotein bearing five discrete aspar-
agine-linked glycans (Fig. 3, indicated by boldN), with glycosyl-
ation of Asn-395 and Asn-520 being critical for normal secre-
tion and function (29). SMPDL3A contains seven potential
N-linked glycosylation motifs (defined by the pattern NX(S/T),
whereX is any amino acid except proline). Notably, two of these
motifs (Asn-222 and Asn-356) are perfectly aligned with the
functionally important Asn-395 and Asn-520 N-linked sites
of aSMase. In summary, comparison of the sequences of
SMPDL3A and SMPDL3B with their homolog aSMase reveals
that both proteins are likely functional members of the metal-
lophosphoesterase enzyme family, although with a potentially
altered substrate preference to aSMase and with distinct cellu-
lar trafficking and localization.
Because of the similarity of SMPDL3A to aSMase, particu-
larly in their metallophosphodiesterase catalytic domains, we
examined the possibility that expression of these two proteins is
co-regulated in response to cholesterol loading, LXR ligand, or
cAMP treatments. In contrast to the marked up-regulation of
SMPDL3A mRNA in HMDMs after cholesterol loading or
stimulation with LXR ligands, aSMase/SMPD1 mRNA was
more moderately up-regulated by acetylated LDL loading and
entirely unaffected by either cholesterol/-methyl cyclodextrin
or T-0901317 treatment (Fig. 1C). Expression of SMPDL3B
mRNA was extremely low in untreated HMDMs and was not
increased further after cholesterol loading (data not shown).No
change in SMPDL3B protein levels in HMDMs or THP-1
macrophages after treatment with T-0901317 was detected
(supplemental Fig. 1, A and B). Expression of aSMase/SMPD1
mRNA was similarly unaffected by treatment with Bt2cAMP
and forskolin (Fig. 2A), indicating insensitivity to elevated cel-
lular cAMP levels. Together, these results show that despite
overall sequence similarity, expression of SMPDL3A and its
homologs is regulated by distinct stimuli.
SMPDL3A Is an N-Linked Glycoprotein and Is Present in
Human and Mouse Blood—As our sequence analysis of
SMPDL3A predicts multiple sites ofN-linked glycosylation, we
considered that one or more bands of SMPDL3A identified by
Western blotmight represent glycosylated forms of the protein.
To test this, whole cell lysates and conditioned media from
HMDMs stimulated with 1 M T-0901317 were digested with
PNGaseF, an enzyme that removes N-linked glycans. For both
cellular and secreted proteins, this treatment resulted in the
disappearance of the original bands and the appearance of a
single SMPDL3A band with a lower apparent molecular mass
(45 kDa), corresponding to the removal of 8 kDa of
N-linked glycans (Fig. 4A).
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As SMPDL3A was found to be secreted from primary
macrophages, we hypothesized that itmay also circulate in vivo.
To investigate this, freshly isolated sera from five healthy,
fasted donors were probed using Western blotting with anti-
SMPDL3A antibody, revealing a band of similar size to
SMPDL3A secreted by HMDMs (Fig. 4B). Interestingly, there
was marked variation between donors in the amount of circu-
lating SMPDL3A protein. Digestion of total human serumwith
PNGaseF reduced the apparent molecular mass of SMPDL3A
on a Western blot (Fig. 4C), demonstrating that circulating
human SMPDL3A is also N-glycosylated. However, the
decrease in apparent molecular mass after PNGaseF digestion
of serum SMPDL3A was less than that for SMPDL3A freshly
secreted by HMDMs (5 versus 8 kDa), suggesting that either
glycan trimming occurs in the circulation or that circulating
SMPDL3A originates from a different tissue source to macro-
phages, which differs in its degree and/or type of N-glycosyla-
tion of SMPDL3A.
SMPDL3A is also present in mouse plasma (wild-type
C57/black), detected with a commercial antibody specific to
murine SMPDL3A (Fig. 4D). In contrast to circulating human
SMPDL3A, the apparent molecular mass of mouse plasma
SMPDL3A was 62 kDa. This mass was consistent with that
observed in conditioned media from the mouse J774 macro-
phage cell line (Fig. 4D). These results further reinforce that
the mature mass of secreted SMPDL3A is tissue- and/or
species-dependent.
Recombinant Expression andPurification ofHumanSMPDL3A—
To study the biochemical function of SMPDL3A, stable CHO
(CHO-SMPDL3A) and HEK (HEK-SMPDL3A) cell lines were
created, expressing full-length human SMPDL3A with a C-ter-
minal His6 tag, under the control of a tetracycline (tet)-induci-
ble promoter. Western blot analysis of CHO-SMPDL3A (Fig.
5A) and HEK-SMPDL3A (supplemental Fig. 1C) cell lysates
after overnight tet induction revealed amajor band of52 kDa
apparentmolecularmass, consistentwith the size of SMPDL3A
endogenously expressed in HMDM. Aminor band of65 kDa
was also observed in tet-induced CHO- and HEK-SMPDL3A
lysates. Negligible leaky expression of human SMPDL3A was
observed in CHO or HEK-SMPDL3A lysates in the absence of
tet induction. Expression of human SMPDL3A had no detect-
able effect on cell growth or viability in the CHO or HEK
cell line (data not shown). In both tet-induced CHO- and
HEK-SMPDL3A cells, no additional (nonspecific) bands were
observed using the 6E3G4A1 monoclonal antibody, demon-
strating the high specificity of this reagent for human
SMPDL3A (Fig. 5A and supplemental Fig. 1C).
As in primary HMDMs, SMPDL3A was secreted into the
media of tet-induced CHO- and HEK-SMPDL3A cells (Fig. 5A
and supplemental Fig. 1C). Recombinant secreted SMPDL3A
has an apparent molecular mass of65 kDa, corresponding to
the size detected inmouse plasma and conditionedmurine J774
macrophage media (Fig. 4F). This species also corresponds to
the minor intensity 65-kDa band detected in CHO- and HEK-
FIGURE4.SMPDL3A is secreted fromHMDMs,N-glycosylated, andpresent inhumanserum.A,HMDMcell lysates andconditionedmedia fromT-0901317-
treated cells were incubated	 PNGaseF, separated by SDS-PAGE, and analyzed by Western blotting for human SMPDL3A as described under “Experimental
Procedures.” B, SMPDL3A in fasted plasma from five healthy volunteers. Equal volumes of plasma (equivalent to 200 nl of neat plasma) were separated by
SDS-PAGE and detected by anti-SMPDL3AWestern blot. Area of negative staining above SMPDL3A band is due to human serum albumin. C, human plasma is
N-glycosylated. 200 nl of neat plasma fromahealthy donorwas incubated	PNGaseF and analyzedby anti-SMPDL3AWestern blotting.D, SMPDL3A inmouse
plasma (equivalent to 200 nl of neat plasma) and conditioned media from J774 macrophages, analyzed using anti-mouse SMPDL3AWestern blotting.
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SMPDL3A lysates, possibly representing SMPDL3A transiting
through the secretory pathway. SMPDL3A secreted from
CHO- andHEK-SMPDL3A cells is 10–15 kDa larger than both
the intracellular and secreted forms in HMDM cells and that
found in human plasma, further indicating theremay be tissue-
and/or species-specific differences in the post-translational
modification of SMPDL3A.
Recombinant His6-tagged SMPDL3A was purified from the
media of tetracycline-induced CHO-SMPDL3A cells using
nickel affinity chromatography, yielding a single detectable
species on Coomassie Blue SDS-polyacrylamide gel of 65
kDa, corresponding to bands detected by Western blotting
with either anti-SMPDL3A 6E3G43A1 or His6 antibodies
(Fig. 5B).
FIGURE 5. Expression, secretion, purification, glycosylation, and localization of recombinant human SMPDL3A in CHO cells. A, expression of human
SMPDL3A in CHO-SMPDL3A cells was induced by addition of 	 tetracycline (1 M, 16 h). Levels of SMPDL3A in cell lysates (10 g of protein/lane) and
conditionedmedia (20l protein/lane)weremeasuredby SDS-PAGEandWesternblotting.B,purificationofHis6-taggedSMPDL3A secreted from tetracycline-
induced CHO-SMPDL3A cells with Ni2 affinity chromatography. Purified material was analyzed using anti-SMPDL3A and anti-His6 Western blotting. Purity
analyzed by Coomassie-stained SDS-PAGE. C, N-glycosylation of human SMPDL3A in tetracycline-induced CHO-SMPDL3A cells was analyzed by digestion of
whole cell lysates and conditioned media with PNGaseF. Changes in molecular mass of SMPDL3A after PNGaseF digestion were measured by SDS-PAGE and
visualized byWestern blotting.D,CHO-SMPDL3A cells after inductionwith 1M tetracycline overnightwere fixedwith 3.7%paraformaldehyde in PBS, stained
with a polyclonal antibody directed against human SMPDL3A (Abcam), and visualized with confocal microscopy. Subcellular localization of human SMPDL3A
in tetracycline-induced CHO-SMPDL3A cells was determined by co-immunofluorescent staining with antibodies against human SMPDL3A (green) and organ-
elle markers (red) BiP (endoplasmic reticulum), LAMP-1 (lysosome), and giantin (Golgi).
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As in HMDMs, both the intracellular and secreted
SMPDL3A fromCHO-SMPDL3A areN-glycosylated, based on
their decreased apparent molecular masses after PNGaseF
digestion (Fig. 5C). The 10–15-kDa difference in apparent
molecular mass between SMPDL3A secreted from HMDMs
andCHO-SMPDL3A cells was largely lost after PNGaseF treat-
ment, indicating the higher mass of recombinant versus endog-
enous human SMPDL3A is largely due to N-linked glycans.
Both the 52- and 65-kDa intracellular forms detected in
CHO-SMPDL3A cells are glycosylated, as both bands are
eliminated after PNGaseF treatment. A small difference in
molecular mass between intracellular and secreted SMPDL3A
remained after PNGaseF digestion, suggesting other still
unknown protein processing or post-translational modifica-
tions may be present.
Intracellular Localization of Human SMPDL3A in CHO
Cells—Immunofluorescent microscopy of human SMPDL3A
expressed in CHO-SMPDL3A cells showed a predominantly
perinuclear pattern, with additional small punctate structures
visible throughout the cell (Fig. 5D). Co-staining with antibod-
ies against organellar markers revealed the majority of human
SMPDL3A to be co-localized with the Golgi marker protein,
Giantin. There was little evidence for co-localization of
SMPDL3A with the lysosome marker, LAMP-1, in contrast
with the typical lysosomal residence of mature intracellular
aSMase (30, 31) nor was co-localization with the endoplasmic
reticulummarker BiP observed. No indication of SMPDL3A in
the plasma membrane was observed, unlike the plasma mem-
brane lipid raft localization in kidney podocytes of homolog
SMPDL3B (32). The identity of the multiple small punctate
SMPDL3A-positive structuresmay represent secretory vesicles
but requires further investigation to confirm this.
Characterization of the Enzymatic Activity of Recombinant
Human SMPDL3A Using Classical Phosphodiesterase Sub-
strates—The enzymatic activity of recombinant cellular and
secreted human SMPDL3A from tet-induced CHO-SMPDL3A
cells was measured using a panel of p-nitrophenol-conjugated
synthetic substrates. Hydrolysis of these substrates at the phos-
phodiester bond releases the p-nitrophenol group, with a cor-
responding increase in absorbance at 405 nm. For each sub-
strate, cell lysates or conditioned media from noninduced
CHO-SMPDL3A cells were used as negative controls. Signifi-
cantly increased activity was detected in conditioned media
from tet-induced cells against the generic phosphodiesterase
substrate bis-p-NPP, the phosphorylcholine analog p-NPPC,
and the nucleotide analog p-NP-TMP (Fig. 6A), demonstrating
secreted SMPDL3A possesses both phosphodiesterase and
nucleotide phosphoesterase activities. Negligible activity was
detected against the classical alkaline phosphatase substrate
(p-NPP), indicating secreted SMPDL3A does not possess
phosphatase/monophosphoesterase activity. As expected,
high background levels of phosphatase/monophosphoesterase
activity against p-NPP were detected in whole cell lysates. Oth-
erwise, data from cell lysates provide the same pattern of
SMPDL3Aactivity for phosphodiester-containing substrates as
for conditioned media (Fig. 6B). To rule out possible off-target
effects of tetracycline induction, nontransfected parental
CHO-Trex cells were treated overnight with 1 M tetracycline.
No significant difference in p-NPPC hydrolyzing activity was
observed between CHO-Trex cells with or without tetracycline
(Fig. 6C), demonstrating that increased enzymatic activities in
CHO-SMPDL3A cells are due to increased SMPDL3A expres-
sion, rather than off-target effects of tetracycline induction.
The pH dependence on the activity of secreted recombinant
SMPDL3A with both p-NPPC and p-NP-TMP substrates
was measured over the range 4.0 to 9.0 (Fig. 6D). Secreted
SMPDL3A exhibited optimal activity against both substrates in
the range pH 4.0–6.0, with activity being significantly reduced
at pH above 7.
The effect of divalent metal ions on secreted SMPDL3A
activity was examined, using both p-NPPC and p-NP-TMP as
substrates (Fig. 6E). Preincubation of SMPDL3A with 10 mM
EDTA for 30 min before the start of the assay inhibited activity
relative to unsupplemented samples but did not completely
abolish activity. Supplementation of the reaction with either
5 mMCa2orMg2had amoderate stimulatory effect, whereas
5 mM Zn2 virtually abolished all activity. This result contrasts
with the enzymology of aSMase, which utilizes Zn2 ions as a
metal co-factor (13, 33).
Lack of Sphingomyelinase Activity for Recombinant Human
SMPDL3A—As shown in Fig. 6, cellular and secreted recombi-
nant human SMPDL3A hydrolyzes p-NPPC, a synthetic analog
of the phosphorylcholine headgroup of lipids such as sphingo-
myelin and phosphatidylcholine. To determine whether this
translated to activity against authentic sphingomyelin, assays
were performed on cell lysates from tetracycline-induced
CHO-SMPDL3A cells, using 3H-labeled sphingomyelin/Triton
X-100 micelles as a substrate, at both acidic and neutral pH. As
expected, both acid and neutral sphingomyelinase activities
were detected in both tet-induced and control CHO-
SMPDL3A lysates, with acid sphingomyelinase activity being
the predominant type (Fig. 7A). However, tet-induced overex-
pression of SMPDL3A did not result in an increase of either
acid or neutral sphingomyelinase activities compared with
uninduced controls, indicating that overexpression of
SMPDL3A does not detectably contribute to sphingomyelin
hydrolysis at either pH.
The activity of SMPDL3A secreted from CHO-SMPDL3A
cells was also tested using the [3H]sphingomyelin/TritonX-100
micelle assay at neutral pH (7.4). As for cell lysates, no differ-
ence in sphingomyelin hydrolysis was detected in conditioned
media collected from tet-induced CHO-SMPDL3A cells versus
noninduced controls (Fig. 7B). As SMPDL3A is present in the
mammalian circulation (Fig. 4, B–D), we considered the possi-
bility that secreted recombinant SMPDL3A lacked an essential
co-factor found only in serum. To test this possibility, condi-
tioned medium from tet-induced CHO-SMPDL3A cells was
supplemented with pooled human serum containing lipopro-
tein-equilibrated [3H]sphingomyelin, which had beenHI (56 °C
for 30 min) to eliminate any endogenous serum sphingomyeli-
nase activity. However, no increase in [3H]sphingomyelin
hydrolysis was detected in conditionedmedia from tet-induced
CHO-SMPDL3A cells supplemented with HI serum versus HI
serum alone (Fig. 7C). A positive control reaction supple-
mented with recombinant Bacillus cereus neutral sphingomy-
elinase showed abundant cleavage of the [3H]sphingomyelin
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NOVEMBER 21, 2014•VOLUME 289•NUMBER 47 JOURNAL OF BIOLOGICAL CHEMISTRY 32905
 at UQ Library on September 5, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
substrate, indicating that HI human serum did not contain an
inhibitor of the hydrolysis reaction.
We also used an alternative method of assaying sphingomy-
elinase activity, using a commercially available enzymatically
coupled assay, based on Amplex Red fluorescence detection of
phosphorylcholine released from the hydrolysis of unlabeled
sphingomyelin/Triton X-100 micelles. Again, no difference in
enzyme activity could be detected between tet-induced and con-
trol CHO-SMPDL3A cell lysates or conditioned media samples
using this assay at either pH 5.5 or 7.4 (data not shown). Using the
Amplex Red kit, we also investigated whether SMPDL3A could
utilize phosphatidylcholine (prepared as Triton X-100 micelles at
the same concentration as for sphingomyelin). As for sphingomy-
elin, no difference was detected between tet-induced and control
CHO-SMPDL3A-conditioned media with phosphatidylcholine
substrate (data not shown).
Artificial overexpression of aSMase in human cells results in
increased levels of intracellular ceramide, a product of sphin-
gomyelin hydrolysis, which are detectable using mass spec-
trometry (34). As it was possible that our in vitro sphingomy-
elinase assays lacked an essential co-factor or condition only
present within an intact cellular environment, we examined
whether SMPDL3A overexpression in human cells was associ-
ated with increased ceramide and/or reduced sphingolipid lev-
els. A lipidomic profile of 285 individual cellular ceramides,
sphingolipid, phospholipid, and sterol species was measured
using tandem mass spectrometry in tet-induced HEK-
SMPDL3A cells and noninduced controls (n  6 each for
FIGURE 6. Activity of recombinant human SMPDL3A against synthetic p-nitrophenyl phosphodiester substrates. A, activity of conditioned serum-free
media harvested from 1 106 control or tetracycline-induced CHO-SMPDL3A cells against p-NPP, bis-p-NPP, p-NPPC, and p-NP-TMP. In each case, the final
substrate concentrationwas20mM, in125mMTris, pH7.0, 5mMMg2.B,activityof cell lysates fromcontrol or tetracycline-inducedCHO-SMPDL3Acells against
substrates listed in A. C, parental nontransfected CHO-Trex or transfected CHO-SMPDL3A cells were treated with or without 1 M tetracycline, and relative
phosphodiesterase activity against 20 mM p-NPPC substrate was measured in whole cell lysates (125 mM Tris, pH 7.0, 5 mMMg2, 1 h at 37 °C). Activity values
were normalized to noninduced CHO-Trex cell lysates. Effect of pH (D) or EDTA/metal ions (E) on relative activity against 20 mM p-NP-TMP and p-NPPC for
purified recombinant SMPDL3A is shown. Activity valueswere normalized to p-NP-TMP at pH 7 or nometal supplementation, respectively. For all experiments
involving cell lysates or conditioned media, tetracycline induction was 1 M final concentration for 16 h. Data are means	 S.D. of three determinations.
SMPDL3A, Cholesterol-regulated Nucleotide Phosphodiesterase
32906 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 47•NOVEMBER 21, 2014
 at UQ Library on September 5, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
induced and control cells, Fig. 7D, inset). No significant differ-
ences were detected in the levels of any assayed lipid species
between SMPDL3A-overexpressing HEK cells and controls
(Fig. 7D). The unperturbed lipid concentrations in SMPDL3A-
overexpressing HEK cells indicates that SMPDL3A likely has
no activity against any major natural phospholipid or sphingo-
lipid substrate in this environment. In conclusion, we have been
unable to demonstrate that either intracellular or secreted
recombinant human SMPDL3A exhibits any enzymatic activity
against sphingomyelin or any other phosphorylcholine-con-
taining lipid substrate.
Recombinant Human SMPDL3A Is a Nucleotide Phospho-
diesterase—As recombinant human SMPDL3A is capable of
utilizing the nucleotide analog p-NP-TMP as a substrate, we
FIGURE 7. Sphingomyelinase activity assays of recombinant human SMPDL3A. A, sphingomyelinase activity assay of lysates of CHO-SMPDL3A cells
treated	 tetracycline (1 M, 16 h), using [3H]choline methyl-labeled sphingomyelin/Triton X-100 micelles as substrate under acidic (pH 5.5; 100 mM sodium
acetate, 5 mM Zn2) or neutral (pH 7.5; 100 mM Tris, 5 mM Mg2) conditions. B, sphingomyelinase activity assay of conditioned serum-free media from
CHO-SMPDL3A cells treated	 tetracycline at pH7.5 under conditions described inA.C, sphingomyelinase activity assay ofHI pooledhuman serumcontaining
1 Ci if [3H]sphingomyelin (SM). HI serum/sphingomyelin mixtures were supplemented (50% v/v) either with water, 1 unit of B. cereus neutral sphingomyeli-
nase, or conditioned serum-free media from tetracycline-induced (1 M, 16 h) CHO-SMPDL3A cells. D, lipidomic MS/MS analysis of SMPDL3A-overexpressing
human cells. Inset, HEK-SMPDL3A cells were grown to near-confluency in 75-cm2 flasks and treated with or without 1M tetracycline for 24 h (n 6 flasks for
each treatment), and whole cell lysates were prepared. Expression of SMPDL3A was examined by Western blotting with 6E3G4A1 anti-SMPDL3A antibodies.
Total cellular lipidswereextracted from lysates, and lipidomicprofilesweregeneratedby tandemLC-MS/MS. Lipid concentrations for eachclass arenormalized
to that of the noninduced control cells. No significant differences in the concentrations of any examined lipid class exist between SMPDL3A-induced and
-uninduced cells (unpaired two-tailed t test). Lipid class abbreviations are as follows: BMP, bis(monoacylglycerol)phosphate; CE, cholesterol esters; Cer, cer-
amide; COH, free cholesterol; DHC, dihexosylceramide; dhCer, dihydroceramide; GM, gangliosides; MHC, monohexosylceramide; PG, phosphatidylglycerol;
THC, trihexosylceramide;DG, diacylglycerol; TG, triacylglycerol; LPC, lysophosphatidylcholine; LPAF, lyso-platelet-activating factor; LPE, lysophosphatidyletha-
nolamine; LPI, lysophosphatidylinositol; oddPC, odd chain phosphatidylcholine; PC, phosphatidylcholine; PC(O), alkyphosphatidylcholine; PC(P), phosphati-
dylcholineplasmalogen;PI,phosphatidylinositol; SM, sphingomyelin;PE,phosphatidylethanolamine;PE(O), alkylphosphatidylethanolamine;PE(P), phosphati-
dylethanolamine plasmalogen; PS, phosphatidylserine.
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also screened the activity of SMPDL3A against a panel of cyclic,
mono-, di-, and tri-phosphate nucleotides. Using themalachite
green phosphate detection assay, we determined that condi-
tioned media from tet-induced CHO-SMPDL3A cells exhib-
ited significantly increased activity against nucleotide triphos-
phates (ATP, CTP, GTP, and UTP) relative to media from
uninduced control cells (Fig. 8A). All nucleotide triphosphates
were hydrolyzed with approximately equal affinity. Significant
activity against nucleotide diphosphates (ADP,GDP, andUDP)
was also detected in tet-induced versus uninduced CHO-
SMPDL3A media, although the level of this activity was sub-
stantially lower than that against triphosphate substrates. No
significant activity was observed against the nucleotide mono-
phosphate AMP, which is consistent with the lack of activity
against the monophosphoester substrate p-nitrophenyl phos-
phate (Fig. 8A). Despite hydrolysis of the phosphodiester bond
in p-NP-TMP, SMPDL3Aexhibited negligible phosphodiester-
ase activity against authentic cyclic nucleotide substrates 3–5-
cAMP or 3–5-cGMP (data not shown). As for synthetic
phosphodiester substrates, SMPDL3A exhibited an acidic pH
optimum when hydrolyzing ATP as a substrate (pH optimum
4–5). Moderate inhibition of activity was observed at pH 7
using TrisHCl as a buffer versus sodium acetate (Fig. 8B).
To determine the position of nucleotide phosphate cleavage
by SMPDL3A, reversed-phase HPLC was used to separate and
identify the products of ATP hydrolysis by SMPDL3A secreted
from tet-inducedCHO-SMPDL3A cells at pH 7.0. ADPwas the
major product of SMPDL3A activity against ATP, accounting
for 100% of reaction product at after 1 h, and 85% of total
product after 4 h. This indicates that SMPDL3A preferentially
hydrolyzes the-phosphate bondofATP, acting as a nucleotide
phosphodiesterase. Minor levels of AMP are detected after 4 h
of incubation, most likely arising from the further release of a
single phosphate from ADP. This is consistent with the ability
of SMPDL3A to hydrolyze ADP, albeit at a reduced rate com-
pared with ATP (Fig. 8A). No other nucleotide species, partic-
ularly adenosine, were detected on the 254 nm absorbance UV
HPLC trace after 4 h of incubation, eliminating the -phos-
FIGURE 8. A, nucleotide phosphodiesterase activity of recombinant SMPDL3A against nucleotide phosphate substrates. The activity of concentrated and
buffer-exchangedconditionedmedia fromCHO-SMPDL3Acells treatedwithorwithout 1M tetracycline for 16hwasdeterminedagainst apanel of nucleotide
phosphates. Activity wasmeasured by colorimetric detection at 620 nmof released inorganic phosphate. Concentrated conditionedmediumwasmixedwith
reaction buffer in a 1:1 v/v ratio. Final reaction conditions were 100 mM Tris, pH 7.0, 5 mMMg2, and 200 M nucleotide phosphate. Data are means	 S.D. of
three determinations. B, pH dependence of purified recombinant SMPDL3A on ATP hydrolytic activity (100 mM sodium acetate, pH 4–7, 100 mM Tris, pH 7).
Reverse phase HPLC analysis of reaction products after incubation of ATP with conditioned media from tetracycline-induced (C) and noninduced control (D)
CHO-SMPDL3A cells. Reaction mixture was 100 M ATP, 100 mM sodium acetate, pH 7. Detection of nucleotide products was performed by measuring
absorbance at 254 nm. Representative chromatograms showing retention times for nucleotide species for induced and noninduced samples are shown in E
and F, respectively.
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phate bond of ATP as a significant site of hydrolysis by
SMPDL3A. In conclusion, when presented with ATP as a sub-
strate, SMPDL3A acts as a nucleotide phosphodiesterase, pre-
dominantly cleaving the -phosphate bond.
SMPDL3A Is the Predominant LXR-regulated Secreted Nucleo-
tide Phosphodiesterase in Human Macrophages—In addition to
human SMPDL3A expressed in CHO cells, we also assessed
thenucleotide phosphodiesterase activities of SMPDL3Asecreted
from LXR-stimulated human THP-1 macrophages, using
p-NP-TMP and ATP as substrates. The specific contribution of
SMPDL3A to enzymatic activity was determined by knocking
down SMPDL3A expression with siRNA and comparing activity
with scrambled nonsilencing siRNA-treated control cells. As for
primary HMDM macrophages, stimulation of THP-1 macro-
phages with the LXR ligand T-0901317 significantly increased
secretionofSMPDL3Aabovebasal levels (Fig. 9A), consistentwith
previous studies (8, 9). Of note, the molecular mass of secreted
SMPDL3A from THP-1 cells is greater than that from HMDMs
and is comparable with the recombinant enzyme produced in
CHO-SMPDL3A cells (65 kDa; Fig. 9A, inset panel). siRNA
knockdown of SMPDL3A expression was highly effective, with
levels of secretedSMPDL3Afallingbelowthoseof scramblednon-
silencing siRNA/DMSO-treated control cells, even after LXR
stimulation (Fig. 9A).
After LXR stimulation, secreted nucleotide phosphodiester-
ase activities against p-NP-TMP and ATP substrates were
FIGURE9.SecretedSMPDL3A levels andp-NP-TMP/ATPhydrolytic activity fromLXR-agonist treatedhumanmacrophages.A,PMAdifferentiatedTHP-1
macrophages grown in RPMI 1640 medium, 10% FBS were transfected with 50 pmol of SMPDL3A siRNA or scrambled nonsilencing control for 24 h, followed
by replacement with serum-free RPMI 1640 medium containing 1 M T-0901317 or DMSO. Media were harvested after 24 h, concentrated, and analyzed by
anti-SMPDL3AWesternblot.B,nucleotidephosphoesteraseactivity fromconditioned serum-freemediapreparedas inAwasmeasuredusing20mMp-NP-TMP
as a substrate (reaction buffer 100mM sodium acetate pH 6.0). Reaction was allowed to proceed overnight at 37 °C, and hydrolysis of the p-NP-TMP substrate
wasdeterminedbymeasuringA405 nm.C,phosphate release fromATP in conditionedmedia as inAmeasuredbyMalachiteGreen assay. Reactionbuffer 200M
ATP, 100 mM TrisHCl, pH 7.0. D,Western blot analysis of CD39 protein levels in whole cell lysates of THP-1 cells treated as in A. F, cell surface-associated ATP
hydrolytic activity of THP-1 cells treated as inA, measured byMalachite Green phosphate detection assay. Reaction conditionswere 200MATP, 150mMNaCl,
2 mM CaCl, 5 mM KCl, 20 mM HEPES, pH 7.4.
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increased 3.4- and 2-fold versus controls, respectively (Fig. 9, B
andC). These increases in secreted nucleotide phosphodiester-
ase activity appears to be entirely attributable to SMPDL3A, as
knockdown of SMPDL3A abolished the effect of LXR stimula-
tion (Fig. 9, B and C). SMPDL3A also appears to be solely
responsible for secreted nucleotide phosphodiesterase activity
frommacrophages under basal nonstimulated conditions, as all
activity was abolished in DMSO-treated cells after SMPDL3A
knockdown (Fig. 9B).
Macrophages express ectonucleotide triphosphate diphos-
phohydrolase 1 (ENTPD1, also known as CD39) on their sur-
face (35). CD39 is anchored to the plasma membrane and
degrades nucleotide tri- and di-phosphates in the extracellular
media (36). To compare the relative activities of cell surface
CD39 and secreted SMPDL3A,we alsomeasured cellular CD39
protein expression levels and cell surface-associated hydrolysis
of phosphate from ATP from LXR-stimulated THP-1 cells in
the same experiment as in Fig. 9, A–C. In contrast to the secre-
tion of SMPDL3A, cellular levels of CD39 protein were unaf-
fected by LXR stimulation with 1 M T-0901317 (Fig. 9D).
siRNA knockdown of SMPDL3A also had no effect on CD39
protein levels. As expected, THP-1 cells exhibited high levels of
cell surface ATP hydrolysis (mean activity 214.4 pmol of PO4/
1 106 cells/min) (Fig. 9E), and this activity was unaffected by
knockdown of SMPDL3A. Cell surface-associated ATP hydro-
lytic activitywas also insensitive to LXR stimulation, in contrast
to the doubling of SMPDL3A-specific activity (Fig. 9C). In
absolute terms, secreted SMPDL3A activity after LXR stimula-
tion is100-fold lower than that occurring at the cell surface at
neutral pH.
DISCUSSION
Our microarray study of cholesterol-loaded primary human
macrophages led to the identification of SMPDL3A as a novel
cholesterol-regulated gene, andwe present the first experimen-
tal evidence of an enzymatic activity for this protein. Our
results confirm bioinformatic predictions that SMPDL3A
encodes a functional phosphodiesterase, as demonstrated by its
ability to hydrolyze the phosphodiester-containing substrates
bis-p-NPP and p-NPPC. Despite significant amino acid
sequence homology with aSMase, we were unable to demon-
strate that recombinant human SMPDL3A could utilize sphin-
gomyelin as a substrate under standard in vitro assay conditions
or affect intracellular sphingolipid, ceramide, or other lipid lev-
els when overexpressed in a human cell line. Unexpectedly,
SMPDL3A exhibits a nucleotide phosphodiesterase activity,
hydrolyzing the synthetic nucleotide p-NP-TMP and releasing
phosphate from natural nucleotide di- and tri-phosphates at an
acidic pH optimum. SMPDL3A more efficiently utilizes nucle-
otide triphosphates versus diphosphates, hydrolyzing them at
the -phosphate bond. Lack of activity against p-nitrophenol
phosphate and the nucleotide monophosphate AMP indicates
SMPDL3A does not possess a monophosphoesterase or 5-ad-
enine monophosphatase activity, such as CD73/5-nucleotid-
ase (37).
We have for the first time shown that levels of SMPDL3A
mRNA, intracellular protein, and secretion are all up-regulated
in response to raised cholesterol levels in primary human
macrophages. This effect appears to be independent of the
means used to deliver cholesterol to the cell, being observed
after both scavenger receptor-mediated uptake of acetylated
LDL or direct delivery to the plasma membrane using choles-
terol-CD complexes. We hypothesize that in the atheroscle-
rotic lesion, densely populated with cholesterol-enriched
macrophage foam cells, SMPDL3A expression will also be sig-
nificantly raised. In support of this hypothesis,microarray anal-
ysis of human carotid atherosclerotic plaque tissue by other
groups has indicated that SMPDL3A forms part of a gene
expression signature that is indicative of inflamed foam cell-
rich plaque tissue (38), and SMPDL3A is the fifth most up-reg-
ulatedmRNA in symptomatic (unstable) plaque tissue obtained
from carotid endarterectomy patients (39). Furthermore, our
re-analysis of publicly available microarray expression data
using the NCBI GEO database and GEO2R tool (40) (accession
number GSE21419) reveals that Smpdl3a mRNA is signifi-
cantly up-regulated in laser-capture microdissected atheroscle-
rotic plaques from apoE/ mice, versus the adjacent healthy
adventitial tissue (41,42). In this study,neitherSmpd1/aSMasenor
Smpdl3bmRNAwereup-regulated inplaques versushealthy arte-
rial tissue, providing in vivo support of our observation that tran-
scriptional regulation of SMPDL3A is highly distinct from that
of its closest homologs. Together, these results indicate that
SMPDL3A expression is indeed raised in the atherosclerotic
lesions in vivo and may be a specific feature of macrophage foam
cells, rather than a generalized tissue response to increased circu-
lating cholesterol levels or development of the lesion. As our
results show that secretion of SMPDL3A from HMDMs is also
significantly increased after cholesterol loading, this suggests that
foam cell-derived SMPDL3A may diffuse into other areas of the
plaque and surrounding tissue, creating an SMPDL3A-enriched
microenvironment.
We present the first evidence that expression and secretion
of SMPDL3A is not only stimulated by LXR agonists but also by
raised intracellular cAMP levels. This stimulation was unaf-
fected by pharmacological inhibition of PKA, indicating the
involvement of alternative cAMP signaling systems, such as
exchange protein directly activated by cAMP (Epac) (43). Fur-
ther studies could confirm this involvement, by use of Epac
mutants and Epac-specific agonists such as 8-(4-chlorophenyl-
thio)-2-O-Me-cAMP. The contribution of the putative cyclic
AMP-responsive element sequences in the SMPDL3A pro-
moter remains to be confirmed bymutational analysis and pro-
moter binding studies.
The physiological significance of cAMP in the regulation of
SMPDL3A expression is unknown at present. Levels of CD39 in
murine macrophages (44) and human endothelial cells (45) are
both increased by raised cAMP concentrations, and this has
been hypothesized to play a role in enhancing vascular anti-
thrombotic properties. As the nucleotide phosphate substrate
specificity of CD39 overlaps with SMPDL3A, there exists the
potential for complementary cAMP-driven anti-thrombotic
roles at the cell surface and in the extracellular milieu for CD39
and SMPDL3A, respectively.
This study has demonstrated that SMPDL3A is modified by
N-linked glycosylation and that the degree of glycosylation var-
ies by cell type, tissue, and species. SMPDL3A contains seven
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potential N-linked motifs, and differences in the degree of gly-
cosylation may represent variable occupancy of these sites.
N-Linked glycosylation of two discrete asparagine residues of
aSMase are required for secretion and correct folding of the
enzyme, and enzymatic deglycosylation of aSMase results in
complete loss of activity (29). The position of both of these
asparagine residues are conserved in SMPDL3A, suggesting
that glycosylationmay play an important role in controlling the
behaviors of SMPDL3A as well. Determining the sites and
structures of theN-linked glycans of SMPDL3A, as well as their
relationship to the cellular origin, secretion, and activity of the
enzyme, should be a focus of future studies.
We have shown that SMPDL3A hydrolyzes synthetic phos-
phodiester and nucleotide di- and tri-phosphate (but not
phosphomonoester or nucleotide monophosphate) substrates
at acidic and neutral pH, with negligible activity at alkaline pH.
SMPDL3A activity is not completely inhibited by preincuba-
tion with EDTA (25 and 66% inhibition for p-NP-TMP and
p-NPPC substrates, respectively), indicating it is a metalloen-
zyme, potentially with bound metal ions being relatively inac-
cessible to direct chelation. SMPDL3A activity is moderately
stimulated by Mg2 and Ca2 ions but strongly inhibited by
Zn2.
Recombinant human SMPDL3A in a CHO expression sys-
tem is detected predominantly in theGolgi, with no evidence of
lysosomal localization. This set of properties contrasts with
those of its homolog aSMase/SMPD1, which is stimulated by
Zn2 and is found intracellularly in the endosomal/lysosomal
system (13, 33). Notably, we were unable to demonstrate that
recombinant human SMPDL3A was capable of hydrolyzing
sphingomyelin, the eponymous substrate of aSMase. Key fea-
tures in the amino acid sequence of SMPDL3Amay account for
these divergent properties, including lack of a saposin lipid acti-
vator domain, nonconservation of a putative aSMase phospho-
rylcholine binding domain, and a predicted signaling domain
with minimal similarity to that of aSMase. Regulation of the
expression of SMPDL3A and aSMase in primary macrophages
is also distinct. In contrast to SMPDL3A, we found that expres-
sion of aSMase/SMPD1mRNA is not up-regulated in HMDMs
in response to raised cholesterol or cAMP levels nor by treat-
ment with LXR agonists, which is consistent with earlier
reports (9). Taken together, these differences in enzymological
properties, intracellular localization, and gene regulation indi-
cate that SMPDL3A likely has a distinct physiological role to its
homolog aSMase.
It is important to note that our results do not absolutely pre-
clude sphingomyelin or other sphingolipids/phospholipids
from being substrates of SMPDL3A. Our assay conditions may
not be optimal for this activity, may lack an essential cofactor,
or present the sphingomyelin substrate in an inappropriate
form. For example, the secreted form of aSMase will not hydro-
lyze sphingomyelin at neutral pH in the commonly used sphin-
gomyelin/Triton X-100 micelle assay, but it exhibits robust
activity when the sphingomyelin substrate is presented as a
component of oxidized LDL (4). Similarly, human intestinal
alkaline sphingomyelinase activity is dependent on the pres-
ence of specific bile salts and is inhibited by Triton X-100/sph-
ingomyelin micelles (46). We are continuing to investigate
alternative conditions under which SMPDL3A may hydrolyze
sphingomyelin or other lipids.
The ability of SMPDL3A to hydrolyze p-NP-TMP and nucle-
otide di- and triphosphates at neutral pH is analogous to certain
members of the nucleotide phosphodiesterase/pyrophospha-
tase (47) and ecto-nucleoside triphosphate diphosphohydro-
lase (48) families. These enzymes are capable of hydrolyzing
phosphoanhydride bonds of ATP and ADP to produce AMP,
which may subsequently degrade to adenosine (a potent anti-
inflammatory signal) by the action of 5-nucleotidase/CD73
(49, 50). Because these enzymes are either secreted or mem-
brane-anchored with their catalytic domains oriented toward
the extracellular space, they play a major role in regulating the
levels of nucleotide phosphates in the circulation. Extracellular
nucleotides such at ATP and UTP, together with their cellular
P2Y/P2X receptors, have become recognized as keymodulators
of vascular dynamics, platelet aggregation, inflammation, and
infection (51). Although levels of cell surface/CD39 ATPase
activity are comparatively high in macrophages, several lines of
evidence point toward a unique context for SMPDL3A activity.
SMPDL3A is secreted and is present in the circulation in solu-
ble form, and although certain CD39 isoforms are shed in a
soluble form, CD39 is predominantly cell surface-associated.
Expression and secreted activity of SMPDL3A are stimulated
by LXR agonists, whereas expression of CD39 protein and cell-
surface associated ATP hydrolytic activity in THP-1 macro-
phages are LXR-insensitive. The substrate preference of
secreted SMPDL3A isATPADP,whereas soluble isoforms of
CD39, such as CD39-L4, demonstrate a strong preference for
nucleotide diphosphates over triphosphates (52). Finally, the
optimum pH of SMPDL3A is acidic, whereas for CD39 is 8.0,
with activity decreasing by 40% at pH 7.0 (53). There is evi-
dence that acidified microenvironments exist within lipid-rich
areas of atherosclerotic plaques (54), creating a specific context
that would favor both the cholesterol-driven expression and
acid-optimal activity of SMPDL3A.
Stimulation of P2 family receptors such as P2X7 by raised
extracellular ATP or UTP levels activates multiple pro-inflam-
matory responses in immune and endothelial cells, including
increased release of IL-1 (55), IL-18, and TNF (56) and che-
motactic stimuli such as MCP-1. In the context of atheroscle-
rosis, high fat-fed apoE/ mice, which were also deficient in
the ADP receptors P2Y1 (57) or P2Y12 (58), showed signifi-
cantly reduced lesion accumulation, as did apoE/ mice
treated with P2Y6-selective antagonists (59). In human
patients, both ATP levels and expression of the P2X7 receptor
are raised in luminal thrombi and inflammatory infiltrates of
carotid artery plaques (60). Together, these results strongly
suggest a deleterious role for purinergic signaling in the pro-
gression of the atherosclerotic lesion. Given that SMPDL3A is
secreted from cholesterol-loaded macrophages, is present in
the circulation, and is capable of hydrolyzing ATP, UTP, and
other nucleotide phosphates, it is conceivable that SMPDL3A
also plays role in purinergic signaling pathways by reducing
circulating levels of pro-inflammatory nucleotide phosphates.
We have shown that SMPDL3A is largely responsible for
increases in p-NP-TMP and ATP hydrolysis observed in the
media of LXR-stimulated human macrophages. This suggests
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SMPDL3A may also be a significant source of secreted nucleo-
tide phosphodiesterase activity in the cholesterol-rich and
macrophage-dense environment of the atherosclerotic plaque.
This activity, by decreasing the local concentration of nucleo-
tide tri- and di-phosphates (particularly ATP or UTP), may
dampen the activation of pro-inflammatory purinergic signal-
ing receptors. If correct, the responsiveness of SMPDL3A in
macrophages to synthetic LXR ligandsmight make it an attrac-
tive candidate for therapeutic modulation, and it should be a
topic for future investigation.
While our manuscript was in preparation, a study of a novel
acid sphingomyelinase-like protein from the bacterium Ralsto-
nia solanacearum, RsASML, was published (61). Consistent
with our results for human SMPDL3A, R. solanacearum
RsASML exhibited no detectable sphingomyelinase activity but
was capable of hydrolyzing bothATP andADP toAMP (but not
AMP to adenosine). Together with our study, the work of
Airola et al. (61) strongly supports the idea that SMPDL3A (and
possibly the closely related homolog SMPDL3B) possesses an
entirely distinct enzymatic activity to acid sphingomyelinase,
which is regulated independently, and with potentially unique
physiological roles.
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SUPPLEMENTARY FIGURE S1: Full length Western blots of cell lysates prepared from primary 
HMDM, THP-1 and HEK-SMPDL3A cells.  A. Western analysis of whole cell lysates from 1x106 
HMDM cells treated overnight with LXR agonist 1µM T-0901317, or DMSO only control.  15µg total 
protein load per lane.  SMPDL3A was detected by probing with undiluted 6E3G4A1 anti-SMPDL3A 
hybridoma supernatant.  SMPDL3B was detected by probing with anti-SMPDL3B polyclonal antibody 
(Aviva ARP33875, 1:1000 dilution).  Box indicates LXR-dependent regulation of SMPDL3A, and the 
band used for HMDM SMPDL3A protein quantitation throughout this study. B. Western analysis of 
whole cell lysates from 1x106  PMA-differentiated THP-1 macrophages, treated with 1µM T-0901317 or 
DMSO, and probed with 6E3G4A1 or anti-SMPDL3B antibodies as for HMDM samples described in 
panel A.    Box indicates the band used for SMPDL3A protein quantitation.  C. Western analysis of cell 
lysates and conditioned media from HEK-SMPDL3A cells.  Cells were induced overnight with 1µM 
tetracycline or left untreated.  15µg of cell lysate or 20µl of conditioned media loaded per lane, and 
probed with undiluted 6E3G3A1 anti-SMPDL3A hybridoma supernatant.  
 
SUPPLEMENTARY FIGURE S2: Lipidomic MS/MS analysis of SMPDL3A overexpressing human 
cells. A. HEK-SMPDL3A cells were grown to near-confluency in 75cm2 flasks, treated with or without 
1µM tetracycline for 24 hours (n=6 flasks for each treatment) and whole cell lysates prepared.  
Expression of SMPDL3A was examined by Western blotting with 6E3G4A1 anti-SMPDL3A antibodies. 
B. Total cellular lipids were extracted from lysates, and lipidomic profiles generated by tandem LC-
MS/MS.  Lipid concentrations for each class are normalized to that of the non-induced control cells. No 
significant differences in the concentrations of any examined lipid class exist between SMPDL3A 
induced and uninduced cells (unpaired two-tailed t-test).  Lipid class abbreviations: BMP: 
bis(monoacylglycerol)phosphate; CE: cholesterol esters; Cer: ceramide; COH: free cholesterol; DHC: 
dihexosylceramide; dhCer: dihydroceramide; GM: gangliosides; MHC: monohexosylceramide; PG: 
phosphatidylglycerol; THC: trihexosylceramide DG: diacylglycerol; TG: triacylglycerol; LPC: 
lysophosphatidylcholine; LPAF: lyso-platelet activating factor; LPE: lysophosphatidylethanolamine; LPI: 
lysophosphatidylinositol; oddPC: odd chain phosphatidylcholine; PC: phosphatidylcholine; PC(O): 
alkyphosphatidylcholine; PC(P): phosphatidylcholine plasmalogen; PI: phosphatidylinositol; SM: 
sphingomyelin; PE: phosphatidylethanolamine; PE(O): alkylphosphatidylethanolamine; PE(P): 
phosphatidylethanolamine plasmalogen; PS: phosphatidylserine. 
 
SUPPLEMENTARY TABLE 1:  
 
Primer pairs used for quantitative real-time PCR measurements. 
 
Gene Direction Primer sequence 
β-actin F GTCCATGAAGTGTGACGTTGACACCGT 
 R CCTAGAAGCATTTGCGGTGCATG 
HPRT F ATTGTAATGACCAGTCAACAGGG 
 R GCATTGTTTTGCCAGTGTCAA 
SMPDL3a F CAAACTTGTACTACGGCCCAA 
 R ATGGCAGATACCCCACTGGA 
SMPD1 F TCAACCTCGGGCTGAAGAAGGA 
 R CACAGGCCTCAGATGGGCTCA 
SMPDL3B F TGCAGGTGTCCCCATAAGCGC 
 R TCACCATGTCCTTCAGGCTCAGTGT 
 
 
 
 
SUPPLEMENTARY TABLE 2:  
 
Twenty most highly up-regulated genes passing all quality filters in acetylated LDL-loaded 
HMDM cells relative to untreated controls.  Fold up-regulation is the mean value from two 
independent donors.   
 
Gene Name NCBI reference Fold up-regulation with 
cholesterol  
ABCG1 NM_004915 13.51 
SLC4A1 NM_000342 10.36 
WWOX NM_016373 6.11 
PGLYRP4 NM_020393 5.51 
DISC1 AF085943 3.95 
SMPDL3A AK000184 3.85 
ORM1 NM_000607 3.40 
IL18BP AF110801 3.08 
MYLIP NM_013262 2.68 
ABCA1 NM_005502 2.21 
RAM2 AK022955 2.13 
ALOX15B NM_001141 2.09 
CST7 NM_003650 2.01 
ADRP NM_001122 1.82 
HS3ST2 NM_006043 1.81 
APOC1 NM_001645 1.73 
NR1H3 NM_005693 1.72 
FJ00065 AK024472 1.69 
MGC35097 AK002164 1.68 
FABP4 NM_001442 1.65 
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